Your session is about to expire
← Back to Search
Smoking Response Inhibition Training
N/A
Waitlist Available
Led By Robert D Dvorak, PhD
Research Sponsored by North Dakota State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Individuals 18-45 years old, who smoke at least 10 cigarettes/day, score 5 or higher on the Fägerstrom Test of Nicotine Dependence, express a desire to quit, and have no current psychiatric diagnoses.
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group
Summary
The current study tests a response inhibition retraining program, implemented on a mobile device, as a mechanism to increase relapse prevention during a smoking cessation attempt. Study participants (n = 150) are randomly assigned to a control, benign, or intervention condition. They complete 2 weeks of response inhibition retraining, and then engage in a cessation attempt. It is hypothesized that individuals who receive the intervention will have a decreased likelihood of relapse following the cessation attempt. In addition, it is hypothesized that this is due to decreases in implicit smoking motivation as a function of the response inhibition training.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Smoking relapse
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Response Inhibition Training: AExperimental Treatment1 Intervention
In the experimental condition, 20% of responses are no-go, with the majority of no-go responses paired with smoking images.
Group II: Response Inhibition Training: BActive Control1 Intervention
In the active comparator condition, 20% of responses are no-go trials, with no-go responses spread evenly across the various images.
Group III: BenignPlacebo Group1 Intervention
A benign condition has also been added to control for the possibility that response inhibition training, regardless of target, increases behavioral control and hence decreases relapse likelihood. The benign condition has 50% no-go trials, with no-go responses spread evenly across images.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Response Inhibition Training
2014
N/A
~30
Find a Location
Who is running the clinical trial?
North Dakota State UniversityLead Sponsor
21 Previous Clinical Trials
687 Total Patients Enrolled
Robert D Dvorak, PhDPrincipal InvestigatorAmy Scott, PhD